Pfizer Announces Plans To Establish Expanded Access Program For Maraviroc, Investigational HIV CCR5 Antagonist

... Pfizer announced today that it plans to establish a multi-national Expanded Access Program (EAP) to make the investigational CCR5 antagonist maraviroc, currently in ongoing phase 3 clinical trials, available to HIV/AIDS patients with CCR5-tropic HIV-1 who have limited or no approved treatment options due to resistance or intolerance. [click link for full article] ...